How best to protect your patients at risk for fracture? Test your knowledge with this 10-question quiz.
Results of a recent meta-analysis fly in the face of established guidelines.
High-risk patients, such as older women, are most likely to benefit.
Concurrent use of biologic therapies for RA and osteoporosis poses no higher risk of serious opportunistic infections.
Study findings may help guide rheumatologists plan long-term therapy for patients dealing with low bone mass.
Both romosozumab and calcium help fracture prevention, and most young adults have fractures at nonosteoporotic sites.
In the ARCH trial, romosozumab plus alendronate outperformed alendronate alone in reducing fracture risk.
The latest research findings reveal new aspects of diagnosis, treatment, and prevention.
An ICER analysis and expert commentary on anabolics’ benefits and costs offer some opposing views, and some consensus.
Only a minority of postmenopausal women reported using appropriate therapy other than estrogen to reduce future fractures.